ZyVersa Therapeutics Faces Delisting Concerns
Ticker: ZVSA · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 8-K |
| Filed Date | Mar 1, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $5,000,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
ZyVersa Therapeutics might get delisted, big trouble for the stock.
AI Summary
ZyVersa Therapeutics, Inc. filed an 8-K on March 1, 2024, to report a notice of delisting or failure to meet continued listing standards. The company was formerly known as Larkspur Health Acquisition Corp. and changed its name on April 26, 2021.
Why It Matters
This filing indicates potential issues with ZyVersa Therapeutics' ability to remain listed on its stock exchange, which could significantly impact its stock value and liquidity.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a public exchange, posing a significant risk to investors.
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Registrant
- Larkspur Health Acquisition Corp. (company) — Former company name
- April 26, 2021 (date) — Date of name change
- February 29, 2024 (date) — Earliest event reported
- March 1, 2024 (date) — Filing date
FAQ
What specific listing standard did ZyVersa Therapeutics fail to meet?
The filing does not specify the exact listing standard that ZyVersa Therapeutics failed to meet, only that it received a notice of delisting or failure to satisfy a continued listing rule or standard.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 29, 2024.
When did ZyVersa Therapeutics change its name from Larkspur Health Acquisition Corp.?
ZyVersa Therapeutics changed its name from Larkspur Health Acquisition Corp. on April 26, 2021.
What is the principal executive office address for ZyVersa Therapeutics?
The principal executive offices of ZyVersa Therapeutics are located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.
What is the filing date of this 8-K report?
This 8-K report was filed on March 1, 2024.
Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-03-01 16:30:15
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZVSA The Nasdaq Global Ma
- $5,000,000 — ue of Publicly Held Shares ("MVPHS") of $5,000,000 for continued listing on the Nasdaq Glo
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-008508.txt ( ) — 206KB
- zvsa-20240229.xsd (EX-101.SCH) — 3KB
- zvsa-20240229_lab.xml (EX-101.LAB) — 33KB
- zvsa-20240229_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZyVersa Therapeutics, Inc. March 1, 2024 By: /s/ Stephen Glover Name: Stephen Glover Title: Chief Executive Officer